CA2988245C - Constructions d'anticorps anti-cd70 et cd3 - Google Patents

Constructions d'anticorps anti-cd70 et cd3

Info

Publication number
CA2988245C
CA2988245C CA2988245A CA2988245A CA2988245C CA 2988245 C CA2988245 C CA 2988245C CA 2988245 A CA2988245 A CA 2988245A CA 2988245 A CA2988245 A CA 2988245A CA 2988245 C CA2988245 C CA 2988245C
Authority
CA
Canada
Prior art keywords
seq
nos
seqid
antibody construct
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2988245A
Other languages
English (en)
Other versions
CA2988245A1 (fr
Inventor
Tobias Raum
Wibke Deisting
Claudia Bluemel
Marc Panzer
Patrick Hoffmann
Elisabeth Nahrwold
Olivier Nolan-Stevaux
Ralf Lutterbuese
Original Assignee
Amgen Research Munich GmbH
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH, Amgen Inc filed Critical Amgen Research Munich GmbH
Priority claimed from PCT/EP2016/068294 external-priority patent/WO2017021354A1/fr
Publication of CA2988245A1 publication Critical patent/CA2988245A1/fr
Application granted granted Critical
Publication of CA2988245C publication Critical patent/CA2988245C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente divulgation concerne une construction d'anticorps bispécifique comprenant un premier domaine de liaison qui se lie au CD70 humain sur la surface d'une cellule cible et un second domaine de liaison qui se lie au CD3 humain sur la surface d'un lymphocyte T. De plus, la divulgation concerne un polynucléotide codant pour la construction d'anticorps, un vecteur comprenant ledit polynucléotide et une cellule hôte transformée ou transfectée avec ledit polynucléotide ou vecteur. Un procédé de production de la construction d'anticorps selon la divulgation, un usage médical de ladite construction d'anticorps et un kit la comprenant sont en outre décrits.
CA2988245A 2015-07-31 2016-08-01 Constructions d'anticorps anti-cd70 et cd3 Active CA2988245C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562199935P 2015-07-31 2015-07-31
US62/199,935 2015-07-31
US201662290886P 2016-02-03 2016-02-03
US62/290,886 2016-02-03
PCT/EP2016/068294 WO2017021354A1 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps anti-cd70 et cd3

Publications (2)

Publication Number Publication Date
CA2988245A1 CA2988245A1 (fr) 2017-02-09
CA2988245C true CA2988245C (fr) 2025-12-23

Family

ID=

Similar Documents

Publication Publication Date Title
US12304952B2 (en) Antibody constructs for DLL3 and CD3
US20230272113A1 (en) Antibody constructs for flt3 and cd3
US11926666B2 (en) Bispecific antibody constructs for CDH3 and CD3
US11155629B2 (en) Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3
US20210284748A1 (en) Antibody constructs for cd70 and cd3
IL256873B (en) Constructs for bispecific antibodies that bind to masotilin and cd3 and uses thereof
CA2988245C (fr) Constructions d'anticorps anti-cd70 et cd3
HK1255589B (en) Antibody constructs for cd70 and cd3